Management strategies for patients with KRAS mutations

Stephen Leong, S Gail Eckhardt, Wells A. Messersmith

Research output: Contribution to journalReview article

Abstract

In an era of targeted therapies and personalized medicine, the search for predictive and prognostic biomarkers has reached the forefront in cancer research. Testing for KRAS mutation status in the treatment of colorectal cancer (CRC) has now become standard of care, especially for patients being considered for treatment with antibodies to the epidermal growth factor receptor (EGFR). Because metastatic CRC patients whose tumors harbor KRAS mutations do not respond to EGFR-targeting antibodies, their management is challenging. As our understanding of the role of KRAS mutations grows, new treatment strategies are being devised but are not yet ready for clinical use. In this review, we examine some of these potential strategies.

Original languageEnglish (US)
Pages (from-to)199-205
Number of pages7
JournalCurrent Colorectal Cancer Reports
Volume6
Issue number4
DOIs
StatePublished - Oct 1 2010

Fingerprint

Mutation
Epidermal Growth Factor Receptor
Colorectal Neoplasms
Precision Medicine
Antibodies
Therapeutics
Standard of Care
Neoplasms
Biomarkers
Research

Keywords

  • Colorectal cancer
  • KRAS
  • KRAS mutations
  • Novel therapeutics

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Cite this

Management strategies for patients with KRAS mutations. / Leong, Stephen; Eckhardt, S Gail; Messersmith, Wells A.

In: Current Colorectal Cancer Reports, Vol. 6, No. 4, 01.10.2010, p. 199-205.

Research output: Contribution to journalReview article

Leong, Stephen ; Eckhardt, S Gail ; Messersmith, Wells A. / Management strategies for patients with KRAS mutations. In: Current Colorectal Cancer Reports. 2010 ; Vol. 6, No. 4. pp. 199-205.
@article{ee60f9e80f474d489c59ec7721305ea7,
title = "Management strategies for patients with KRAS mutations",
abstract = "In an era of targeted therapies and personalized medicine, the search for predictive and prognostic biomarkers has reached the forefront in cancer research. Testing for KRAS mutation status in the treatment of colorectal cancer (CRC) has now become standard of care, especially for patients being considered for treatment with antibodies to the epidermal growth factor receptor (EGFR). Because metastatic CRC patients whose tumors harbor KRAS mutations do not respond to EGFR-targeting antibodies, their management is challenging. As our understanding of the role of KRAS mutations grows, new treatment strategies are being devised but are not yet ready for clinical use. In this review, we examine some of these potential strategies.",
keywords = "Colorectal cancer, KRAS, KRAS mutations, Novel therapeutics",
author = "Stephen Leong and Eckhardt, {S Gail} and Messersmith, {Wells A.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1007/s11888-010-0066-x",
language = "English (US)",
volume = "6",
pages = "199--205",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "4",

}

TY - JOUR

T1 - Management strategies for patients with KRAS mutations

AU - Leong, Stephen

AU - Eckhardt, S Gail

AU - Messersmith, Wells A.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - In an era of targeted therapies and personalized medicine, the search for predictive and prognostic biomarkers has reached the forefront in cancer research. Testing for KRAS mutation status in the treatment of colorectal cancer (CRC) has now become standard of care, especially for patients being considered for treatment with antibodies to the epidermal growth factor receptor (EGFR). Because metastatic CRC patients whose tumors harbor KRAS mutations do not respond to EGFR-targeting antibodies, their management is challenging. As our understanding of the role of KRAS mutations grows, new treatment strategies are being devised but are not yet ready for clinical use. In this review, we examine some of these potential strategies.

AB - In an era of targeted therapies and personalized medicine, the search for predictive and prognostic biomarkers has reached the forefront in cancer research. Testing for KRAS mutation status in the treatment of colorectal cancer (CRC) has now become standard of care, especially for patients being considered for treatment with antibodies to the epidermal growth factor receptor (EGFR). Because metastatic CRC patients whose tumors harbor KRAS mutations do not respond to EGFR-targeting antibodies, their management is challenging. As our understanding of the role of KRAS mutations grows, new treatment strategies are being devised but are not yet ready for clinical use. In this review, we examine some of these potential strategies.

KW - Colorectal cancer

KW - KRAS

KW - KRAS mutations

KW - Novel therapeutics

UR - http://www.scopus.com/inward/record.url?scp=79952738135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952738135&partnerID=8YFLogxK

U2 - 10.1007/s11888-010-0066-x

DO - 10.1007/s11888-010-0066-x

M3 - Review article

AN - SCOPUS:79952738135

VL - 6

SP - 199

EP - 205

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 4

ER -